Pfizer-Wyeth

This post was commissioned on January 26, 2009, and it was categorized as FDA/Regulatory, M&A.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

: Image via Wikipedia

In my last post, I gave five reason for Pfizer not to buy Wyeth and said I would be astonished if the deal actually went though.

Well… consider me astonished.

My favorite part of the press release is the part about a “cost savings of about $4B” by year three.

Awesome!

So, let me get this strait, instead of addressing any of the immediate pressing concerns facing the company, a major driver for the deal is a cost savings of $4B in three years.

Great job, you’ve created a solution to a problem that doesn’t exisit pre-merger (i.e., no merger, no need to save $4B) instead of focusing on things that matter (e.g., R&D productivity, patent cliffs, etc…).

Theoretically Related Posts

January 23, 2009 -- 5 Reasons Pfizer Shouldn’t Buy Wyeth and One Reason It Should (1)
February 5, 2009 -- GSK Not Joining Pharma-mergerfest-a-palooza ‘09 (0)
May 6, 2008 -- Bristol-Myers Squibb To Be Acquired By… [Insert Name Here]?? (8)
March 10, 2009 -- Mega-mergers Are Not Good For Business (0)
March 9, 2009 -- Merck to Buy Schering-Plough for $41.1 Billion Cash and Stock Deal (1)
November 5, 2008 -- Another CB-1 Antagonist Bites the Dust: Pfizer Cancels CP-945,598 (0)
October 23, 2008 -- No Rumors For You. Come Back. One Year (0)
October 21, 2008 -- One Man’s Trash: Novartis Buys Nektar’s Pulmonary Division for $115M (0)
October 20, 2008 -- Pfizer and UCB Announce Cyclofluidics: A Joint Venture (0)
October 3, 2008 -- Swami Predicts ImClone’s Future (1)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: